Bavituximab
- Generic Name
- Bavituximab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 648904-28-3
- Unique Ingredient Identifier
- Q16CT95N25
- Background
Bavituximab is a chimeric Anti-PS monoclonal antibody analog which is used to potentially treat cancers and viral infections. It binds to phosphatidylserine and other exposed host cell lipids when induced by cellular stress. Additional analogs in the class include 3G4, 2aG4, 9d2 and Hu3g4.
- Indication
Investigated for use/treatment in breast cancer, cancer/tumors (unspecified), HIV infection, hepatitis (viral, C), and solid tumors.
- Associated Conditions
- -
- Associated Therapies
- -
Safety and Efficacy Study of Bavituximab Plus Paclitaxel and Carboplatin to Treat Breast Cancer
- Conditions
- First Posted Date
- 2008-04-30
- Last Posted Date
- 2011-03-24
- Lead Sponsor
- Peregrine Pharmaceuticals
- Target Recruit Count
- 46
- Registration Number
- NCT00669565
- Locations
- ๐ฎ๐ณ
Rajalakshmi Multispecialty Hospital, Bangalore, India
๐ฎ๐ณApollo Specialty Hospitals, Chennai, India
๐ฎ๐ณNizam's Institute of Medical Sciences, Hyderabaad, India
A Safety and Efficacy Study of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
- First Posted Date
- 2008-04-30
- Last Posted Date
- 2017-04-21
- Lead Sponsor
- Peregrine Pharmaceuticals
- Target Recruit Count
- 46
- Registration Number
- NCT00669591
- Locations
- ๐ฌ๐ช
Ltd. Oncological Center, Batumi, Georgia
๐ฌ๐ชLtd. Chemotherapy and Immunotherapy clinic Medulla 6, Jikia Str, Tbilisi, Georgia
๐ฌ๐ชLtd. Tbilisi Oncological Dispensary, Tblisi, Georgia
Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus
- First Posted Date
- 2007-07-18
- Last Posted Date
- 2011-06-09
- Lead Sponsor
- Peregrine Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT00503347
- Locations
- ๐บ๐ธ
AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
๐บ๐ธJohns Hopkins University, Center for Viral Hepatitis, Baltimore, Maryland, United States
๐บ๐ธSaint Michael's Medical Center, Newark, New Jersey, United States
Repeat-Dose Study of Bavituximab in Patients With Chronic Hepatitis C
- Conditions
- First Posted Date
- 2006-06-23
- Last Posted Date
- 2008-05-07
- Lead Sponsor
- Peregrine Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT00343525
- Locations
- ๐บ๐ธ
University Hepatitis Center at Bach & Godofsky MD PA, Sarasota, Florida, United States
๐บ๐ธAlamo Medical Research, San Antonio, Texas, United States
Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies
- First Posted Date
- 2005-08-11
- Last Posted Date
- 2011-03-01
- Lead Sponsor
- Peregrine Pharmaceuticals
- Target Recruit Count
- 28
- Registration Number
- NCT00129337
- Locations
- ๐บ๐ธ
Arizona Cancer Center, Tucson, Arizona, United States
๐บ๐ธThe West Clinic, Memphis, Tennessee, United States
๐บ๐ธPremiere Oncology, Santa Monica, California, United States
Study of Bavituximab in Patients With Chronic Hepatitis C Virus Infection
- Conditions
- First Posted Date
- 2005-08-09
- Last Posted Date
- 2008-05-07
- Lead Sponsor
- Peregrine Pharmaceuticals
- Target Recruit Count
- 32
- Registration Number
- NCT00128271
- Locations
- ๐บ๐ธ
Bach & Godofsky, MD, PA, Bradenton, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.